The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders

Prashant Tibrewal; Milanduth K. Kanigere; Jeffrey C.L. Looi; Stephen Allison; Tarun Bastiampillai

doi:10.1177/00048674221087163

The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders

Prashant Tibrewal, Milanduth K. Kanigere, Jeffrey C.L. Looi, Stephen Allison, Tarun Bastiampillai

College of Medicine and Public Health

Research output: Contribution to journal › Comment/debate

2 Citations (Scopus)

Abstract

Anxiety disorders are an important public health issue because they are highly prevalent and approximately 40% are treatment-refractory (Bystritsky, 2006). In a recent commentary, we suggested that the benefits of benzodiazepines for treatment-refractory anxiety disorders have been underestimated and their risks overestimated (Tibrewal et al., 2021a). Carefully prescribed in discussion with patients, benzodiazepines might be a safer option than some alternative agents, such as quetiapine, for long-term treatment.

Lugg’s (2022) response to our commentary (Tibrewal et al., 2021a) questions the strength of the evidence for the long-term use of benzodiazepines in anxiety disorders...

Original language	English
Pages (from-to)	723-724
Number of pages	2
Journal	Australian and New Zealand Journal of Psychiatry
Volume	56
Issue number	6
Early online date	18 Mar 2022
DOIs	https://doi.org/10.1177/00048674221087163
Publication status	Published - Jun 2022

Keywords

Anxiety disorders
Drug effects
Benzodiazepines
Long-term treatment

Access to Document

10.1177/00048674221087163Licence: In Copyright

Cite this

@article{326223fa711e40deaae51e40921c0b40,

title = "The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders",

abstract = "Anxiety disorders are an important public health issue because they are highly prevalent and approximately 40% are treatment-refractory (Bystritsky, 2006). In a recent commentary, we suggested that the benefits of benzodiazepines for treatment-refractory anxiety disorders have been underestimated and their risks overestimated (Tibrewal et al., 2021a). Carefully prescribed in discussion with patients, benzodiazepines might be a safer option than some alternative agents, such as quetiapine, for long-term treatment.Lugg{\textquoteright}s (2022) response to our commentary (Tibrewal et al., 2021a) questions the strength of the evidence for the long-term use of benzodiazepines in anxiety disorders...",

keywords = "Anxiety disorders, Drug effects, Benzodiazepines, Long-term treatment",

author = "Prashant Tibrewal and Kanigere, {Milanduth K.} and Looi, {Jeffrey C.L.} and Stephen Allison and Tarun Bastiampillai",

year = "2022",

month = jun,

doi = "10.1177/00048674221087163",

language = "English",

volume = "56",

pages = "723--724",

journal = "Australian and New Zealand Journal of Psychiatry",

issn = "0004-8674",

publisher = "SAGE Publications Ltd",

number = "6",

}

TY - JOUR

T1 - The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders

AU - Tibrewal, Prashant

AU - Kanigere, Milanduth K.

AU - Looi, Jeffrey C.L.

AU - Allison, Stephen

AU - Bastiampillai, Tarun

PY - 2022/6

Y1 - 2022/6

N2 - Anxiety disorders are an important public health issue because they are highly prevalent and approximately 40% are treatment-refractory (Bystritsky, 2006). In a recent commentary, we suggested that the benefits of benzodiazepines for treatment-refractory anxiety disorders have been underestimated and their risks overestimated (Tibrewal et al., 2021a). Carefully prescribed in discussion with patients, benzodiazepines might be a safer option than some alternative agents, such as quetiapine, for long-term treatment.Lugg’s (2022) response to our commentary (Tibrewal et al., 2021a) questions the strength of the evidence for the long-term use of benzodiazepines in anxiety disorders...

AB - Anxiety disorders are an important public health issue because they are highly prevalent and approximately 40% are treatment-refractory (Bystritsky, 2006). In a recent commentary, we suggested that the benefits of benzodiazepines for treatment-refractory anxiety disorders have been underestimated and their risks overestimated (Tibrewal et al., 2021a). Carefully prescribed in discussion with patients, benzodiazepines might be a safer option than some alternative agents, such as quetiapine, for long-term treatment.Lugg’s (2022) response to our commentary (Tibrewal et al., 2021a) questions the strength of the evidence for the long-term use of benzodiazepines in anxiety disorders...

KW - Anxiety disorders

KW - Drug effects

KW - Benzodiazepines

KW - Long-term treatment

UR - http://www.scopus.com/inward/record.url?scp=85126736072&partnerID=8YFLogxK

U2 - 10.1177/00048674221087163

DO - 10.1177/00048674221087163

M3 - Comment/debate

C2 - 35303778

AN - SCOPUS:85126736072

SN - 0004-8674

VL - 56

SP - 723

EP - 724

JO - Australian and New Zealand Journal of Psychiatry

JF - Australian and New Zealand Journal of Psychiatry

IS - 6

ER -

The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this